Does age at observation time affect the clinical presentation of mild cognitive impairment?

Barbara Vicini-Chilovi1, Maddalena Riva, Marta Conti

  • 1Department of Neurology, University of Brescia, Brescia, Italy. barbaravicini@tiscali.it

Abstract

Insights

Age significantly impacts mild cognitive impairment (MCI) presentation. Very old individuals with MCI exhibit greater executive function decline compared to younger patients, indicating age-related differences in cognitive profiles.

Area of Science:

  • Neuroscience
  • Gerontology
  • Cognitive Psychology

Background:

  • Limited research exists on age-related variations in mild cognitive impairment (MCI) clinical and neuropsychological profiles.
  • Understanding these age-related differences is crucial for accurate diagnosis and management of MCI.

Purpose of the Study:

  • To investigate whether age at evaluation influences the clinical, functional, or cognitive characteristics of individuals diagnosed with MCI.
  • To identify specific cognitive domains affected by age in the MCI population.

Main Methods:

  • 167 outpatients with a clinical diagnosis of MCI were enrolled.
  • Demographic and clinical characteristics were recorded.
  • A comprehensive neuropsychological assessment was administered to all participants.

Main Results:

  • MCI patients were categorized into three age groups: young (≤69), old (70-79), and very old (≥80).
  • No significant differences were observed in demographics, general cognition, or memory impairment across age groups.
  • Very old MCI subjects demonstrated significantly greater impairment in executive functions compared to younger MCI patients.
  • A higher proportion of very old MCI patients were classified as having multiple-domain amnestic MCI.

Conclusions:

  • Age demonstrably affects the clinical presentation of mild cognitive impairment.
  • Very old individuals with MCI show poorer performance across multiple cognitive abilities, especially executive functions, compared to younger counterparts.
  • These findings underscore the importance of considering age when assessing and characterizing MCI.

Related Concept Videos

Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
Cognitive Development During Adulthood01:30

Cognitive Development During Adulthood

Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...